Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AMRI to buy ComGenex
February 6, 2006
| A version of this story appeared in
Volume 84, Issue 6
Chemistry service provider Albany Molecular Research Inc. has agreed to acquire ComGenex, a privately held drug discovery services company in Budapest, Hungary. ComGenex was founded in 1992 and had contract revenue of about $8.5 million last year. It employs 119 people, including 88 scientific and technical staff. According to AMRI, ComGenex combines parallel synthesis with computational chemistry to create libraries of small molecules with druglike characteristics. AMRI CEO Thomas E. D'Ambra notes that ComGenex is based in a European Union member state "with a significantly lower cost structure than Western European countries."
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X